Covid19
Conditions
Keywords
Ivermectin, Doxycycline, COVID-19, Coronavirus, SARS-CoV-2
Brief summary
A randomized controlled trial on using Ivermectin and doxycycline to treat mild-moderate outpatients, severe, and critical inpatients of Coronavirus disease 19 (COVID-19) along with standard of care. Seventy Iraqi COVID-19 patients received Ivermectin and Doxycycline plus standard of care versus seventy Iraqi COVID-19 patients received standard of care only. .
Detailed description
Objectives: COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try old re-purposed drugs on COVID-19. Methods: Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters.
Interventions
DRUGIvermectin and Doxycyline
Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.
DRUGStandard of care
Standard care * Acetaminophen 500mg on need * Vitamin C 1000mg twice/ day * Zinc 75-125 mg/day * Vitamin D3 5000IU/day * Azithromycin 250mg/day for 5 days * Oxygen therapy/ C-Pap if needed * dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed * Mechanical ventilation, if needed
Sponsors
Alkarkh Health Directorate-Baghdad
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
16 Years to 86 Years
Healthy volunteers
No
Inclusion criteria
* COVID-19 patients at any stage of this disease
Exclusion criteria
* Patients of allergic history to Ivermectin or to doxycyline
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality rate | Up to 8 weeks | The effect of the experimental drugs to reduce the mortality rate (death rate) of treated patients |
| Rate of progression disease | up to 8 weeks | rate of patients under treatment who undergo progression of disease to a more advanced stage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to recovery | Up to 8 weeks | time needed by treated patients to recover (become symptoms free and polymerase chain reaction, or PCR, negative) |
Countries
Iraq
Outcome results
None listed